Abstract
The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Anticonvulsants / administration & dosage*
-
Anticonvulsants / adverse effects
-
Carbamazepine / administration & dosage*
-
Carbamazepine / adverse effects
-
Child, Preschool
-
Confusion / chemically induced
-
Consciousness Disorders / chemically induced
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Epilepsy / drug therapy*
-
Female
-
Humans
-
Male
-
Prospective Studies
-
Secondary Prevention
-
Treatment Outcome
Substances
-
Anticonvulsants
-
Carbamazepine